The effect of glycopyrroniumbromide on hypersalivation in patients with Parkinson's disease: a randomised, cross-over, doubleblind, placebocontrolled trial.
Completed
- Conditions
- Parkinsonian patients with hypersalivation
- Registration Number
- NL-OMON20228
- Lead Sponsor
- M.E.L. Arbouw, Hospital Medisch Spectrum TwenteDepartment of clinical pharmacyP.O. Box 50.0007500 KA EnschedeThe Netherlands
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 24
Inclusion Criteria
1. Patients with Parkinson's disease;
2. Age >=18 years;
Exclusion Criteria
1. Hypersensitivity to glycopyrronium bromide, sorbic acid or saccharin sodium;
2. Myasthenia gravis;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of patients with a decrease of 3 points on the hypersalivation score (on a scale from 1-9).
- Secondary Outcome Measures
Name Time Method The difference in mean improvement on the hypersalivation score between the two groups. Furthermore, the difference in<br>reported adverse events will be analysed.